Holen Sie sich die Stockscreener-App
1.70
0.59%
0.01
Handel nachbörslich:
1.67
-0.03
-1.76%
Schlusskurs vom Vortag:
$1.69
Offen:
$1.69
24-Stunden-Volumen:
295.53K
Relative Volume:
1.30
Marktkapitalisierung:
$27.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.29M
KGV:
-2.4286
EPS:
-0.7
Netto-Cashflow:
$-6.47M
1W Leistung:
+16.44%
1M Leistung:
+18.88%
6M Leistung:
+42.86%
1J Leistung:
-25.76%
1-Tages-Spanne:
$1.66
$1.70
1-Wochen-Bereich:
$1.50
$1.70
52-Wochen-Spanne:
$0.94
$2.55
NanoViricides Inc Stock (NNVC) Company Profile
Firmenname
NanoViricides Inc
Sektor
Branche
Telefon
203-937-6137
Adresse
1 Controls Drive, Shelton, CT
Vergleichen Sie NNVC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.70 | 23.47M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2015-02-11 | Eingeleitet | Midtown Partners | Strong Buy |
NanoViricides Inc Aktie (NNVC) Neueste Nachrichten
NanoViricides Inc. Stock Analysis and ForecastHigh-octane gains - jammulinksnews.com
What drives NanoViricides Inc. stock priceUnprecedented growth rates - jammulinksnews.com
How NanoViricides Inc. stock performs during market volatilityFree Consultation - Newser
What analysts say about NanoViricides Inc. stockStrongest growth potential - jammulinksnews.com
Is NanoViricides Inc. a good long term investmentOutstanding capital appreciation - jammulinksnews.com
Measles Now Has a DrugNV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides - Lohud
NanoViricides says lead antiviral boosted survival in measles-infected mice - Proactive financial news
Breakthrough: New Drug NV-387 Could Be First-Ever Treatment for Measles as Global Cases Surge - Stock Titan
Mpox Antiviral Clinical Trial Advances as WHO Extends Global Emergency - Global Biodefense
WHO Extended Global Emergency Status of MPox EpidemicDevelopment of Treatment for MPox with NV-387 is Timely, Says NanoViricides - Great Falls Tribune
NanoViricides Advances MPox Treatment Development Amid WHO's Extended Health Emergency - citybuzz -
NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency - Proactive financial news
D.C. United Roofing Inc. Wins 2025 Consumer Choice Award for Roofing in Barrie - The Palm Beach Post
NanoViricides Targets Multi-Billion MPox Market with Superior Treatment as WHO Extends Global Emergency - Stock Titan
Go Industries Inc. Unveils Durable Winch Grille Guard for Unmatched Vehicle Protection - The Palm Beach Post
What makes NanoViricides Inc. stock price move sharplyReal Time Breakout Tracking - Newser
Why NanoViricides Inc. stock attracts strong analyst attention3x Return Stock Radar - Newser
NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks - Proactive financial news
Small cap wrap: Lisata Therapeutics, Uranium American Resources, Nano One Materials... - Proactive financial news
Market movers: Autodesk, Waters, NanoViricides... - Proactive financial news
NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox - Zacks Small Cap Research
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides - Worcester Telegram
NanoViricides nears completion of clinical trial design for MPox treatment - Proactive financial news
Dallas Central's Welborn Garage Receives 2025 Consumer Choice Award for Garage & Overhead Doors - The Palm Beach Post
Breakthrough MPox Drug NV-387 Targets Deadly Clade I Strain as Phase II Trial Takes Shape - Stock Titan
Finanzdaten der NanoViricides Inc-Aktie (NNVC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):